Analgesia pp 65-93 | Cite as

Antipyretic Analgesics: Nonsteroidal Antiinflammatory Drugs, Selective COX-2 Inhibitors, Paracetamol and Pyrazolinones

  • B. HinzEmail author
  • K. Brune
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 177)


Antipyretic analgesics are a group of heterogeneous substances including acidic (nonsteroidal antiinflammatory drugs, NSAIDs) and nonacidic (paracetamol, pyrazolinones) drugs. Moreover, various selective cyclooxygenase-2 (COX-2) inhibitors with improved gastrointestinal tolerability as compared with conventional NSAIDs have been established for symptomatic pain treatment in recent years. The present review summarizes the pharmacology of all of these drugs with particular emphasis on their rational use based on the diverse pharmacokinetic characteristics and adverse drug reaction profiles. Referring to the current debate, potential mechanisms underlying cardiovascular side effects associated with long-term use of COX inhibitors are discussed.


Nonsteroidal antiinflammatory drugs Selective cyclooxygenase-2 inhibitors Paracetamol Pyrazolinones Pharmacokinetics Mechanisms of hyperalgesia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU (2002) PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 5:34–40PubMedCrossRefGoogle Scholar
  2. Akopian AN, Sivilotti L, Wood JN (1996) A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379:257–262PubMedCrossRefGoogle Scholar
  3. Anonymous (1998) An epidemiologic study of severe anaphylactic and anaphylactoid reactions among hospital patients: methods and overall risks. The International Collaborative Study of Severe Anaphylaxis. Epidemiology 9:141–146CrossRefGoogle Scholar
  4. Baba H, Kohno T, Moore KA, Woolf CJ (2001) Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 21:1750–1756PubMedGoogle Scholar
  5. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M (1996) Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390:165–169PubMedCrossRefGoogle Scholar
  6. Benn SC, Costigan M, Tate S, Fitzgerald M, Woolf CJ (2001) Developmental expression of the TTX-resistant voltage-gated sodium channels Nav1.8 (SNS) and Nav1.9 (SNS2) in primary sensory neurons. J Neurosci 21:6077–6085PubMedGoogle Scholar
  7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528PubMedCrossRefGoogle Scholar
  8. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA (2002) Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci USA 99:7130–7135PubMedCrossRefGoogle Scholar
  9. Brandt K (2003) Paracetamol in the treatment of osteoarthritis pain. Drugs 63 Spec No 2:23–41PubMedCrossRefGoogle Scholar
  10. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102PubMedCrossRefGoogle Scholar
  11. Bridger S, Henderson K, Glucksman E, Ellis AJ, Henry JA, Williams R (1998) Deaths from low dose paracetamol poisoning. BMJ 316:1724–1725PubMedGoogle Scholar
  12. Brune K (1974) How aspirin might work: a pharmacokinetic approach. Agents Actions 4:230–232PubMedCrossRefGoogle Scholar
  13. Brune K, Hinz B (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 33:1–6PubMedCrossRefGoogle Scholar
  14. Brune K, Lanz R (1985) Pharmacokinetics of non-steroidal anti-inflammatory drugs. In: Bonta IL, Bray MA, Parnham MJ (eds) The pharmacology of inflammation. (Handbook of inflammation, vol 5) Elsevier Science, Amsterdam, pp 413–449Google Scholar
  15. Brune K, Zeilhofer HU (2006) Antipyretic analgesics: basic aspects. In: Wall PD, Melzack R (eds) Textbook of pain. Elsevier, LondonGoogle Scholar
  16. Brune K, Glatt M, Graf P (1976) Mechanism of action of anti-inflammatory drugs. Gen Pharmacol 7:27–33PubMedGoogle Scholar
  17. Brune K, Rainsford KD, Schweitzer A (1980) Biodistribution of mild analgesics. Br J Clin Pharmacol 10Suppl 2:279–284Google Scholar
  18. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289:735–741PubMedGoogle Scholar
  19. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817PubMedCrossRefGoogle Scholar
  20. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313PubMedCrossRefGoogle Scholar
  21. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926–13931PubMedCrossRefGoogle Scholar
  22. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539–541PubMedCrossRefGoogle Scholar
  23. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405:183–187PubMedCrossRefGoogle Scholar
  24. Dinchuk JE, Liu RQ, Trzaskos JM (2003) COX-3: in the wrong frame in mind. Immunol Lett 86:121PubMedCrossRefGoogle Scholar
  25. England S, Bevan S, Docherty RJ (1996) PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J Physiol (Lond) 495:429–440PubMedGoogle Scholar
  26. European Agency for the Evaluation of Medicinal Products (2005a) Public statement: European medicines agency concludes action on COX-2 inhibitors. London, 27 June 2005Google Scholar
  27. European Agency for the Evaluation of Medicinal Products (2005b) EMEA, press release: European Medicines Agency update on non-selective NSAIDs. London, 17 October 2005Google Scholar
  28. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364:675–684PubMedCrossRefGoogle Scholar
  29. FDA (2006) FDA News: FDA announces series of changes to the class of marketed nonsteroidal anti-inflammatory drugs (NSAIDs). Cited 8 Apr 2006Google Scholar
  30. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, et al (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 287:64–71PubMedCrossRefGoogle Scholar
  31. Geisslinger G, Menzel S, Wissel K, Brune K (1993) Single dose pharmacokinetics of different formulations of ibuprofen and aspirin. Drug Invest 5:238–242Google Scholar
  32. Gold MS, Reichling DB, Shuster MJ, Levine JD (1996) Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc Natl Acad Sci USA 93:1108–1112PubMedCrossRefGoogle Scholar
  33. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762PubMedCrossRefGoogle Scholar
  34. Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heindl C, Reinold H, Smart TG, Harvey K, Schutz B, Abo-Salem OM, Zimmer A, Poisbeau P, Welzl H, Wolfer DP, Betz H, Zeilhofer HU, Muller U (2004) GlyR α3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304:884–887PubMedCrossRefGoogle Scholar
  35. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312:1563–1566Google Scholar
  36. Hinz B, Brune K (2002) Cyclooxygenase-2—ten years later. J Pharmacol Exp Ther 300: 367–375PubMedCrossRefGoogle Scholar
  37. Hinz B, Brune K, Pahl A (2000a) Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E2 and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 278:790–796PubMedCrossRefGoogle Scholar
  38. Hinz B, Brune K, Pahl A (2000b) Prostaglandin E2 up-regulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 272:744–748PubMedCrossRefGoogle Scholar
  39. Hinz B, Dorn CP, Shen TY, Brune K (2000c) Anti-inflammatory-antirheumatic drugs. McGuire JL (ed) Pharmaceuticals—classes, therapeutic agents, areas of application, vol 4. Wiley-VCH, Weinheim, pp 1671–1711Google Scholar
  40. Hinz B, Kraus V, Pahl A, Brune K (2000d) Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E2 synthesis in murine macrophages. Biochem Biophys Res Commun 274:197–202PubMedCrossRefGoogle Scholar
  41. Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K (2003) Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 74:222–235PubMedCrossRefGoogle Scholar
  42. Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K (2004) Upregulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol 66:1643–1651PubMedCrossRefGoogle Scholar
  43. Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U (2005a) Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol 59: 80–84PubMedCrossRefGoogle Scholar
  44. Hinz B, Rösch S, Ramer R, Tamm E, Brune K (2005b) Latanoprost induces matrix metalloproteinase-1 expression in human non-pigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J 19:1929–1931PubMedGoogle Scholar
  45. Hinz B, Dormann H, Brune K (2006) More pronounced inhibition of cyclooxygenase-2, increase of blood pressure and decrease of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 54:282–291PubMedCrossRefGoogle Scholar
  46. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366PubMedCrossRefGoogle Scholar
  47. Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869–874PubMedCrossRefGoogle Scholar
  48. International Agranulocytosis and Aplastic Anemia Study (1986) Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 256:1749–1757CrossRefGoogle Scholar
  49. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potent novel drug target. Proc Natl Acad Sci USA 96:7220–7225PubMedCrossRefGoogle Scholar
  50. Kaufman DW, Kelly JP, Levy M. Shapiro S (1991) The drug etiology of agranulocytosis an aplastic anemia. Monographs in epidemiology and biostatistics 18. Oxford University Press, LondonGoogle Scholar
  51. Kimmey MB (2004) Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med 117Suppl 5A:72S–78SPubMedGoogle Scholar
  52. Kopp E, Ghosh S (1994) Inhibition of NF-κB by sodium salicylate and aspirin. Science 265:956–959PubMedCrossRefGoogle Scholar
  53. Lopshire JC, Nicol GD (1997) Activation and recovery of the PGE2-mediated sensitization of the capsaicin response in rat sensory neurons. J Neurophysiol 78:3154–3164PubMedGoogle Scholar
  54. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3:927–933PubMedCrossRefGoogle Scholar
  55. Maldve RE, Kim Y, Muga SJ, Fischer SM (2000) Prostaglandin E2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J Lipid Res 41:873–881PubMedGoogle Scholar
  56. Masferrer JL, Zweifel BS, Seibert S, Needleman P (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86:1375–1379PubMedCrossRefGoogle Scholar
  57. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M (1997) Induction of cyclooxygenase 2 in gastricmucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387–397PubMedCrossRefGoogle Scholar
  58. Mockenhaupt M, Schlingmann J, Schroeder W, Schoepf E (1996) Evaluation of non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants as risk factors for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Pharmacoepidemiol Drug Saf 5:116Google Scholar
  59. Muth-Selbach US, Tegeder I, Brune K, Geisslinger G (1999) Acetaminophen inhibits spinal prostaglandin E2 release after peripheral noxious stimulation. Anesthesiology 91: 231–239PubMedCrossRefGoogle Scholar
  60. Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters KM, Chan CC (1999) Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br J Pharmacol 128:853–859PubMedCrossRefGoogle Scholar
  61. Neugebauer V, Geisslinger G, Rümenapp P, Weiretter F, Szelenyi I, Brune K, Schaible HG (1995) Antinociceptive effects of R(−)-and S(+)-flurbiprofen on rat spinal dorsal horn neurons rendered hyperexcitable by an acute knee joint inflammation. J Pharmacol Exp Ther 275:618–628PubMedGoogle Scholar
  62. NIH (2004) NIH News. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer’s disease prevention trial. Cited 8 Apr 2006Google Scholar
  63. Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y (1997) Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 89:1621–1628PubMedGoogle Scholar
  64. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091PubMedCrossRefGoogle Scholar
  65. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, Seo H, Ohta H, Nozawa S, Kudo I, Suda T (1996) IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156:758–764PubMedGoogle Scholar
  66. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125:1481–1492PubMedCrossRefGoogle Scholar
  67. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and-2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48:623–631PubMedGoogle Scholar
  68. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schror K, Weber AA (2005) Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 96:e1–6PubMedCrossRefGoogle Scholar
  69. Ramer R, Weinzierl U, Schwind B, Brune K, Hinz B (2003) Ceramide is involved in R(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 64:1189–1198PubMedCrossRefGoogle Scholar
  70. Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Narumiya S, Muller U, Zeilhofer HU (2005) Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 115:673–679PubMedCrossRefGoogle Scholar
  71. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M Paoletti C, Shapiro S, Sheir N, Schöpf E, Kaufman D (1995) Drug etiology of Stevens-Johnson syndrome and toxic epidermal necrolysis, first results from an international case-control study. N Engl J Med 333:1600–1609PubMedCrossRefGoogle Scholar
  72. Rudy AC, Knight PM, Brater DC, Hall SD (1991) Stereoselective metabolism of ibuprofen in humans: administration of R-, S-and racemic ibuprofen. J Pharmacol Exp Ther 259:1133–1139PubMedGoogle Scholar
  73. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410:471–475PubMedCrossRefGoogle Scholar
  74. Schaible HG, Schmidt RF (1988) Time course of mechanosensitivity changes in articular afferents during a developing experimental arthritis. J Neurophysiol 60:2180–2195PubMedGoogle Scholar
  75. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, Halter F (1998) Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 123:795–804PubMedCrossRefGoogle Scholar
  76. Schnitzer TJ (2002) Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 23Suppl 4:S24–S30PubMedCrossRefGoogle Scholar
  77. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 364:665–674PubMedCrossRefGoogle Scholar
  78. Schwab JM, Beiter T, Linder JU, Laufer S, Schulz JE, Meyermann R, Schluesener HJ (2003) COX-3—a virtual pain target in humans? FASEB J 17:2174–2175PubMedCrossRefGoogle Scholar
  79. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K (2002) Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72:50–61PubMedCrossRefGoogle Scholar
  80. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB (1986) Paracetamol hepatotoxicity in alcoholics. Ann Intern Med 104:399–404PubMedGoogle Scholar
  81. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247–1255PubMedCrossRefGoogle Scholar
  82. Singh G, Miller JD, Huse DM, Pettitt D, D’Agostino RB, Russell MW (2003) Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 30:714–719PubMedGoogle Scholar
  83. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95:13313–13318PubMedCrossRefGoogle Scholar
  84. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRefGoogle Scholar
  85. Tries S, Neupert W, Laufer S (2002) The mechanism of action of the new anti-inflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 51:135–143PubMedCrossRefGoogle Scholar
  86. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 231:232–235PubMedGoogle Scholar
  87. Wallace JL, Ignarro LJ, Fiorucci S (2002) Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov 1:375–382PubMedCrossRefGoogle Scholar
  88. Weissmann G (1993) Prostaglandins as modulators rather than mediators of inflammation. J Lipid Mediat 6:275–286PubMedGoogle Scholar
  89. Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K (2002) Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 16:56–60PubMedCrossRefGoogle Scholar
  90. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K (2003) Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 74:130–137PubMedCrossRefGoogle Scholar
  91. Whelton A, Maurath CJ, Verburg KM, Geis GS (2000) Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7:159–175PubMedCrossRefGoogle Scholar
  92. Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111:544–552PubMedGoogle Scholar
  93. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expressionof a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692–2696PubMedCrossRefGoogle Scholar
  94. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK (1999) Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96:5292–5297PubMedCrossRefGoogle Scholar
  95. Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63:901–907PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  1. 1.Department of Experimental and Clinical Pharmacology and ToxicologyFriedrich Alexander University Erlangen-NurembergErlangenGermany

Personalised recommendations